Recently, Hanudel et al. showed that Vadadustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI), ameliorates CKD-associated anemia and improves iron levels, as well as reducing the loss of kidney function and lowering FGF23 (85). This evidence concerns the gene FGF23 and anemia.